Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN 株式レポート

時価総額:US$1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Supernus Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /66

Supernus Pharmaceuticalsの総株主資本は$929.2M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$1.3Bと$374.9Mです。 Supernus Pharmaceuticalsの EBIT は$5.6Mで、利息カバレッジ比率-0.7です。現金および短期投資は$297.7Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオ-3.7x
現金US$347.19m
エクイティUS$957.45m
負債合計US$358.38m
総資産US$1.32b

財務の健全性に関する最新情報

Recent updates

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

財務状況分析

短期負債: SUPNの 短期資産 ( $544.3M ) が 短期負債 ( $314.6M ) を超えています。

長期負債: SUPNの短期資産 ( $591.0M ) が 長期負債 ( $49.7M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: SUPNは負債がありません。

負債の削減: SUPN負債比率が69%であった 5 年前と比べて負債がありません。

債務返済能力: SUPNには負債がないため、営業キャッシュフロー でカバーする必要はありません。

インタレストカバレッジ: SUPNには負債がないため、利息支払い の負担は問題になりません。


貸借対照表


健全な企業の発掘